On August 18, WUXI XDC rose 3.08% in regular trading, trading at 66.9 HKD/share, with turnover of 29.92 million HKD.

On the news front, the company previously announced that its board will convene on August 24 to review and approve interim results for the first half, with the market holding positive expectations. Fellow WuXi-affiliated company WuXi AppTec reported H1 revenue growth of 38.93% YoY and net profit growth of 29.43%, with management raising full-year guidance, continuing to bolster sector sentiment. On the institutional side, Schroders PLC increased its long position to 5.01% on August 6. Additionally, CLSA raised its target price for the company to 82.6 HKD maintaining an Outperform rating, while Daiwa initiated coverage with a Buy rating and a 78 HKD target price, citing the company's 24% global ADC outsourcing market share.

Within the Life Sciences Tools and Services sector, GENSCRIPT BIO rose 6.6%, WUXI BIO rose 4.38%, and WUXI APPTEC rose 0.59%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)